LabCorp's Liquid Yield Option(TM) Notes Due 2021 and Zero Coupon Convertible Subordinated Notes Due 2021 to Accrue Contingent Interest

BURLINGTON, N.C.--(BUSINESS WIRE)--March 12, 2008--Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE:LH) announced today that for the period of March 12, 2008 to September 11, 2008, its zero coupon subordinated Liquid Yield Option(TM) Notes due 2021 (LYONs) and Zero Coupon

Laboratory Corporation of America(R) Holdings Announces 2007 Fourth Quarter and Full Year Results

Fourth Quarter Net Sales Growth of 11.9% Drives EPS Growth of 21.0% and Operating Cash Flow of $240.4 Million BURLINGTON, N.C.--(BUSINESS WIRE)--Feb. 7, 2008--Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) today announced results for the quarter and year ended December 31,

LabCorp is Scheduled to Present at the UBS Global Healthcare Services Conference

BURLINGTON, N.C.--(BUSINESS WIRE)--Feb. 6, 2008--Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) today announced that David P. King, Chief Executive Officer, and William B. (Brad) Hayes, Executive Vice President and Chief Financial Officer, are scheduled to speak at the UBS

LabCorp is Scheduled to Present at the Wachovia Securities 2008 Healthcare Conference

BURLINGTON, N.C.--(BUSINESS WIRE)--Jan. 28, 2008--Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE:LH) today announced that David P. King, Chief Executive Officer, and Bradford T. Smith, Executive Vice President, Corporate Affairs, are scheduled to speak at the Wachovia Securities

LabCorp Announces Definitive Agreement to Acquire Tandem Labs, Inc.

BURLINGTON, N.C.--(BUSINESS WIRE)--Jan. 24, 2008--Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) and Tandem Labs, a leading bioanalytical and immunoanalytical contract research organization (CRO) supporting pharmaceutical and biotechnology companies with their discovery,

LabCorp(R) Announces the Availability of Affymetrix-Based Whole Genome Microarrays

BURLINGTON, N.C., Jan 22, 2008 (BUSINESS WIRE) -- Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) is pleased to announce the availability of an ultra high-density microarray, Affymetrix based technology (Whole-Genome Sampling Analysis).

LabCorp Licenses Technology for Early Detection of Lung Cancer from Duke University

BURLINGTON, N.C.--(BUSINESS WIRE)--Jan. 17, 2008--Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE:LH) today announced that it has entered into an exclusive license agreement with Duke University Medical Center (Duke) to commercialize Duke's new blood-based assay for early detection

LabCorp is Scheduled to Present at the Merrill Lynch Health Services Investor Conference

BURLINGTON, N.C.--(BUSINESS WIRE)--Nov. 26, 2007--Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE:LH) today announced that William B. (Brad) Hayes, Executive Vice President and Chief Financial Officer, and Bradford T. Smith, Executive Vice President, Corporate Affairs, are

LabCorp Announces $500 Million Stock Repurchase Program

BURLINGTON, N.C.--(BUSINESS WIRE)--Nov. 5, 2007--Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) today announced that its Board of Directors has authorized a new stock repurchase program under which LabCorp may purchase up to an aggregate of $500,000,000 of its Common Stock

LabCorp(R) Launches Integrated and Sequential Prenatal Screening Technology for Down Syndrome

More Sensitive Technology Improves Assessment of Down Syndrome Risk BURLINGTON, N.C.--(BUSINESS WIRE)--Oct. 25, 2007--Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH), an industry leader in prenatal clinical laboratory testing, announced that it now offers Integrated screening